SG11201607458QA - Muscarinic receptor agonists - Google Patents
Muscarinic receptor agonistsInfo
- Publication number
- SG11201607458QA SG11201607458QA SG11201607458QA SG11201607458QA SG11201607458QA SG 11201607458Q A SG11201607458Q A SG 11201607458QA SG 11201607458Q A SG11201607458Q A SG 11201607458QA SG 11201607458Q A SG11201607458Q A SG 11201607458QA SG 11201607458Q A SG11201607458Q A SG 11201607458QA
- Authority
- SG
- Singapore
- Prior art keywords
- receptor agonists
- muscarinic receptor
- muscarinic
- agonists
- receptor
- Prior art date
Links
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 title 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201404922A GB201404922D0 (en) | 2014-03-19 | 2014-03-19 | Pharmaceutical compounds |
| PCT/GB2015/050807 WO2015140559A1 (en) | 2014-03-19 | 2015-03-19 | Muscarinic receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201607458QA true SG11201607458QA (en) | 2016-10-28 |
Family
ID=50635044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201607458QA SG11201607458QA (en) | 2014-03-19 | 2015-03-19 | Muscarinic receptor agonists |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US10030035B2 (en) |
| EP (1) | EP3119396B1 (en) |
| JP (3) | JP6498691B2 (en) |
| KR (1) | KR102368901B1 (en) |
| CN (2) | CN106659719B (en) |
| AP (1) | AP2016009445A0 (en) |
| AU (3) | AU2015233140B2 (en) |
| BR (1) | BR112016021590B1 (en) |
| CA (1) | CA2942187C (en) |
| CL (1) | CL2016002348A1 (en) |
| DK (1) | DK3119396T3 (en) |
| EA (1) | EA031245B1 (en) |
| ES (1) | ES2872378T3 (en) |
| GB (1) | GB201404922D0 (en) |
| HK (1) | HK1231382A1 (en) |
| IL (1) | IL247854B (en) |
| MX (2) | MX2016012103A (en) |
| MY (1) | MY193728A (en) |
| PH (1) | PH12016501791B1 (en) |
| RU (1) | RU2678835C2 (en) |
| SA (1) | SA516371862B1 (en) |
| SG (1) | SG11201607458QA (en) |
| UA (1) | UA120928C2 (en) |
| WO (1) | WO2015140559A1 (en) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6083818B2 (en) | 2011-11-18 | 2017-02-22 | ヘプタレス セラピューティクス リミテッドＨｅｐｔａｒｅｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ | Muscarinic M1 receptor agonist |
| GB201404922D0 (en) | 2014-03-19 | 2014-04-30 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201504675D0 (en) | 2015-03-19 | 2015-05-06 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201513743D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| WO2017107089A1 (en) | 2015-12-23 | 2017-06-29 | Merck Sharp & Dohme Corp. | 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor |
| WO2017112719A1 (en) | 2015-12-23 | 2017-06-29 | Merck Sharp & Dohme Corp. | 6,7-dihydro-5h-pyrrolo[3,4-b]pyridin-5-one allosteric modulators of the m4 muscarinic acetylcholine receptor |
| GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
| WO2018112843A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor |
| WO2018112840A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | 6, 5-fused heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor |
| WO2018112842A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor |
| GB201709652D0 (en) * | 2017-06-16 | 2017-08-02 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| WO2019000238A1 (en) | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | 5-(pyridin-3-yl)oxazole allosteric modulators of m4 muscarinic acetylcholine receptor |
| WO2019000237A1 (en) | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | 3-(1h-pyrazol-4-yl)pyridine allosteric modulators of m4 muscarinic acetylcholine receptor |
| WO2019000236A1 (en) | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | 3-(1h-pyrazol-4-yl)pyridine allosteric modulators of m4 muscarinic acetylcholine receptor |
| TW201922758A (en) | 2017-10-24 | 2019-06-16 | 美商歐樂根公司 | Enamines and diastereo-selective reduction of enamines |
| GB201810239D0 (en) * | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201810245D0 (en) * | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB202020191D0 (en) | 2020-12-18 | 2021-02-03 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB202103211D0 (en) | 2021-03-08 | 2021-04-21 | Heptares Therapeutics Ltd | Pharmaceutical compounds for use in therapy |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999032489A1 (en) * | 1997-12-23 | 1999-07-01 | Alcon Laboratories, Inc. | Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions |
| WO1999032479A1 (en) * | 1997-12-23 | 1999-07-01 | Alcon Laboratories, Inc. | Phthalimide-piperidine, -pyrrolidine and -azepine derivatives, their preparation and their use as muscarinic receptor (ant-)agonists |
| BRPI0507586A (en) | 2004-02-10 | 2007-07-03 | Hoffmann La Roche | ccr5 chemokine receptor modulators |
| NZ555444A (en) | 2004-11-29 | 2011-01-28 | Vertex Pharma | Modulators of muscarinic receptors |
| TW200804382A (en) | 2005-12-05 | 2008-01-16 | Incyte Corp | Lactam compounds and methods of using the same |
| WO2007076070A2 (en) * | 2005-12-22 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
| AU2007221220A1 (en) * | 2006-02-22 | 2007-09-07 | Vertex Pharmaceuticals Incorporated | Spiro condensed piperidnes as modulators of muscarinic receptors |
| WO2008021375A2 (en) | 2006-08-15 | 2008-02-21 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
| JP6083818B2 (en) * | 2011-11-18 | 2017-02-22 | ヘプタレス セラピューティクス リミテッドＨｅｐｔａｒｅｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ | Muscarinic M1 receptor agonist |
| DK2897948T3 (en) * | 2012-09-18 | 2016-12-05 | Heptares Therapeutics Ltd | BICYCLIC AZA RELATIONS AS MUSCARIN M1 RECEPTOR AGONISTS |
| AU2015213900B2 (en) | 2014-02-06 | 2018-12-13 | Nxera Pharma Uk Limited | Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonists |
| GB201404922D0 (en) | 2014-03-19 | 2014-04-30 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| TW201922758A (en) * | 2017-10-24 | 2019-06-16 | 美商歐樂根公司 | Enamines and diastereo-selective reduction of enamines |
-
2014
- 2014-03-19 GB GB201404922A patent/GB201404922D0/en not_active Ceased
-
2015
- 2015-03-19 JP JP2016558078A patent/JP6498691B2/en active Active
- 2015-03-19 BR BR112016021590-7A patent/BR112016021590B1/en active IP Right Grant
- 2015-03-19 CN CN201580014525.3A patent/CN106659719B/en active Active
- 2015-03-19 EA EA201691853A patent/EA031245B1/en unknown
- 2015-03-19 DK DK15713562.5T patent/DK3119396T3/en active
- 2015-03-19 AP AP2016009445A patent/AP2016009445A0/en unknown
- 2015-03-19 ES ES15713562T patent/ES2872378T3/en active Active
- 2015-03-19 WO PCT/GB2015/050807 patent/WO2015140559A1/en active Application Filing
- 2015-03-19 MY MYPI2016001654A patent/MY193728A/en unknown
- 2015-03-19 SG SG11201607458QA patent/SG11201607458QA/en unknown
- 2015-03-19 MX MX2016012103A patent/MX2016012103A/en active IP Right Grant
- 2015-03-19 US US15/126,935 patent/US10030035B2/en active Active
- 2015-03-19 KR KR1020167028884A patent/KR102368901B1/en active IP Right Grant
- 2015-03-19 AU AU2015233140A patent/AU2015233140B2/en active Active
- 2015-03-19 RU RU2016138788A patent/RU2678835C2/en active
- 2015-03-19 CA CA2942187A patent/CA2942187C/en active Active
- 2015-03-19 CN CN201911160130.0A patent/CN110903306B/en active Active
- 2015-03-19 EP EP15713562.5A patent/EP3119396B1/en active Active
- 2015-03-19 UA UAA201610523A patent/UA120928C2/en unknown
-
2016
- 2016-09-13 PH PH12016501791A patent/PH12016501791B1/en unknown
- 2016-09-15 IL IL247854A patent/IL247854B/en active IP Right Grant
- 2016-09-16 CL CL2016002348A patent/CL2016002348A1/en unknown
- 2016-09-19 SA SA516371862A patent/SA516371862B1/en unknown
- 2016-09-19 MX MX2020010674A patent/MX2020010674A/en unknown
-
2017
- 2017-05-18 HK HK17105025.9A patent/HK1231382A1/en unknown
-
2018
- 2018-05-23 US US15/987,506 patent/US10428088B2/en active Active
-
2019
- 2019-03-06 AU AU2019201560A patent/AU2019201560B2/en active Active
- 2019-03-13 JP JP2019046005A patent/JP6660502B2/en active Active
- 2019-09-26 US US16/584,185 patent/US11034704B2/en active Active
-
2020
- 2020-02-07 JP JP2020019478A patent/JP6880260B2/en active Active
- 2020-11-30 AU AU2020280982A patent/AU2020280982A1/en not_active Abandoned
-
2021
- 2021-06-11 US US17/345,557 patent/US20220048928A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1231382A1 (en) | Muscarinic receptor agonists | |
| HK1250160A1 (en) | Muscarinic agonists | |
| HK1252163A1 (en) | Receptor | |
| HK1250139A1 (en) | Muscarinic agonists | |
| IL252257A0 (en) | Insulin receptor partial agonists | |
| GB2531928B (en) | Image-stitching for dimensioning | |
| GB201514875D0 (en) | Receptor | |
| HK1255163A1 (en) | Heteroarylhydroxypyrimidinones as agonists of the apj receptor | |
| GB201817189D0 (en) | Image-stitching for dimensioning | |
| HK1250138A1 (en) | Muscarinic agonists | |
| IL276400A (en) | Dopamine d3 receptor antagonists compounds | |
| EP3126132C0 (en) | Embossing-laminating device | |
| GB201420865D0 (en) | Boring device | |
| HRP20190510T1 (en) | Device for posturography | |
| HK1206552A2 (en) | Wetting device | |
| GB201411628D0 (en) | Device | |
| IL243730A0 (en) | Vasopressin-2 receptor agonists | |
| PL2902265T3 (en) | Monitor holder | |
| GB201506219D0 (en) | Flyfishing Line Holder | |
| GB201312010D0 (en) | Receptor Agonists | |
| GB201400386D0 (en) | Agonists | |
| GB201419430D0 (en) | Dopamine D3 receptor antagonist compounds | |
| GB201419433D0 (en) | Dopamine D3 receptor antagonist compounds | |
| GB201416789D0 (en) | Device Holder | |
| GB201411954D0 (en) | Device |